Cryopreserved human hepatocytes and other in vitro systems often underpredict in vivo intrinsic clearance (CL int ). The aim of this study is to explore the potential utility of 
Introduction
The introduction of a new drug into the market is not only a complex, time-consuming and costly process, but also a risky business. Thus, there is an urgent need for strategies that identify and discard compounds with inappropriate properties at earlier stages of drug discovery. As unsatisfactory pharmacokinetic properties are a major reason for the attrition of candidate drugs in early clinical trials, the importance of pharmacokinetics predictions in the optimisation and selection of drug candidates is increasingly recognized (Ansede and Thakker, 2004) . In particular, great efforts have been made to develop fast, reliable experimental strategies to predict human hepatic metabolic clearance .
Human liver microsomes (HLM) have been mainly used for this purpose (Iwatsubo et al., 1997; Obach, 1999; Riley et al., 2005) . However, underestimation of human clearance using this in vitro system is common for many drugs Hallifax et al., 2005) . More recently, human hepatocytes have also been explored as an alternative in vitro system for clearance predictions. Unlike HLM, intact hepatocytes contain a full complement of metabolic enzymes (Phase I and Phase II) and physiological cofactors, as well as intact cell membranes and transporter proteins. Thus, hepatocytes provide an in vitro system for integrated metabolism and transport studies, and might reflect the in vivo situation more closely than subcellular models. One major limitation for the widespread use of human hepatocytes for clearance studies is the scarcity of high-quality fresh human liver required for cell harvesting. Technical advances in freezing protocols have made cryopreserved human hepatocytes available from commercial suppliers, which has notably enabled their application for hepatic clearance studies (Bachmann et al., 2003; Naritomi et al., 2003; McGinnity et al., 2004) .
Compared to microsomes, the use of hepatocytes appears to be a significant improvement in the accuracy of clearance predictions because of the reduced bias (Brown et al., 2007) . However, cryopreserved hepatocytes are not fully quantitative for predictions as a systematic underprediction of the in vivo value is obtained Brown et al., 2007) .
Recombinant cytochrome P450 (P450) enzymes have also been proved as in vitro systems for human metabolic clearance predictions (Proctor et al., 2004; Stringer et al., 2009) . A previous study showed improved reliability of cDNA-expressed P450 enzymes in relation to HLM or hepatocytes (Stringer et al., 2009) . A potential advantage of the high P450 levels of recombinant systems is enhanced assay sensitivity, This article has not been copyedited and formatted. The final version may differ from this version. forms or for lower clearance drugs. Compared with hepatocytes, however, one major drawback is the lack of intact membranes and transport mechanisms.
The adenovirus vector strategy has been successfully used for introducing target genes into hepatocytes and other liver-derived cells (Castell et al., 1997; Bai and Cederbaum, 2004; Naiki et al., 2004; Vignati et al., 2005; Aoyama et al., 2009) . A major characteristic of this approach is that protein expression can be modulated as a function of the level of adenovirus infection. In the present study, we investigated the suitability of a cell system based on an adenoviral-mediated expression of individual P450 enzymes (Ad-CYP) in HepG2 cells as an alternative in vitro system for predicting the metabolic clearance of drugs. The HepG2 cell model was selected for the study because of its human liver origin, their content in NAPH-cytochrome P450 reductase and cytochrome b5 (Rodriguez-Antona et al., 2002; Gonzalez and Korzekwa, 1995) and because it has been reported as an adequate host system for the transient expression of P450 enzymes (Vignati et al., 2005; Aoyama et al., 2009 Construction of recombinant adenoviruses. CYP3A4 cDNA (2.1 kb) was released from the mammalian expression vectors pCI-CYP3A4 (Jover et al., 1996) . The coding cDNA sequence of human CYP1A2 was obtained from human liver mRNA through high-fidelity RT-PCR, and CYP2C9 cDNA from cells previously generated in our laboratory (Bort et al., 1999) . Primers were designed using a specific primer analysis software (Oligo 4.0), and the "wild-type" allele CYP1A2 or CYP2C9 sequences were selected from the GeneBank/EMBL database. Both the forward and reverse primers sequences are listed in Table 1 . The amplified PCR products were purified by column chromatography (the High Pure PCR Product Purification Kit, Roche) and the presence of a unique DNA band of the expected size was confirmed by agarose gel electrophoresis. Purified CYP cDNAs were double digested with the appropriate restriction enzymes and ligated into the adenoviral pAC/CMVpLpA plasmid (GomezFoix et al., 1992) which was previously digested with the same restriction enzymes to provide a directional cohesive cloning. Constructs were confirmed by restriction enzyme analysis and were sequenced to ensure that the cloned CYP cDNA was 100% homologous with the described wild-type sequence.
Each recombinant plasmid pAC/CMVpLpA containing CYP cDNA (transfer vector) was cotransfected with pJM17 (McCroy et al., 1988) into 293 cells (AdE1A-transformed human embryonic kidney cells) by calcium phosphate/DNA coprecipitation to obtain a recombined adenovirus expressing each P450 isoform (named Ad-CYP1A2, Ad-CYP2C9 and Ad-CYP3A4) (Becker et al., 1994 Incubation conditions. Assays were performed by incubation of Ad-CYP HepG2 cells cultured in 24-well plates with selected substrates. For each assay, optimal conditions were selected in terms of incubation time, cell density and adenovirus dose to ensure that they were within the linear range (see Table 2 for detailed conditions). Substrates were added in dimethyl sulfoxide or methanol, at such concentrations that the final solvent concentration did not exceed a 0.5% (v/v) when added to the incubation medium. Metabolite formation kinetics studies were performed in 3-4 independent Ad-CYP-transduced cell cultures using at least seven concentrations of the substrates. All incubations were performed in duplicate.
In brief, a volume of 250 μl of warmed (37ºC) incubation medium (Na 2 HPO 4 1 mM, 137 mM NaCl, 5 mM KCl, 0.5 mM MgCl 2 , 1 mM CaCl 2 , 10 mM glucose, and 10 mM This article has not been copyedited and formatted. The final version may differ from this version. well, centrifuged at 1000 x g, and the supernatant (80 μl) was stored at -80ºC. After incubating cells with the substrate at 37ºC for the appropriate time (Table 2) , aliquots of the incubation medium were taken and centrifuged as described above. Prior to metabolite analysis, samples were incubated with β-glucuronidase and arylsulfatase for 2 h at 37ºC to hydrolyse any glucuronide and/or sulfate conjugates formed (Donato et al., 1993) . Hydrolysis reactions were stopped by diluting (1:2) in the quenching solution (cold acetonitrile). Samples were collected and stored at -80°C until analysis.
To quantitatively compare the data obtained from Ad-CYP HepG2 cells with those from human hepatocytes, we used a Relative Activity Factor (RAF), calculated as the ratio of a specific marker activity in primary cultured human hepatocytes to the same activity in RAF was defined by Crespi (1995) to obtain quantitative comparisons between cDNAexpressed P450s and HLM by assuming that the correlations obtained from the marker substrate can be extrapolated to other substrates for the same P450 enzyme. 7-Ethoxyresorufin O-deethylation, diclofenac 4'-hydroxylation and testosterone 6β-hydroxylation were used as marker reactions for CYP1A2, CYP2C9 and CYP3A4, respectively. Marker activities were measured in each Ad-CYP HepG2 preparation.
Data from hepatocytes are an average of at least twelve independent cultures (Donato et al., 1999 (Donato et al., , 2006 . For both Ad-CYP HepG2 and primary human hepatocytes, activities were assayed by direct incubation of cell monolayers with 10 μM 7-ethoxyresorufin, 10
μM diclofenac or 200 μM testosterone for 60, 120 or 60 min, respectively (Donato et al., 2006) . Chromatography was performed at 35ºC, and an aliquot (20 µl) of incubation extract was injected into a Teknokroma C18 column (100 mm × 2.1 mm, 3μm particle size) at a flow rate of 0.4 ml/min. The mobile phase was 0.1% formic acid in acetonitrile (A) and 0.1% formic acid in water (B). The proportion of acetonitrile was increased linearly from 0 to 90% in 6 min, and then the column was allowed re-equilibration at the initial conditions for 4 min. The column eluent was directed to an electrospray ionisation interface without splitting, operating at 320ºC and using nitrogen as cone gas (50 l/h).
The MS/MS analysis was carried out with a triple quadrupole analyzer operating in the multiple reaction monitoring mode using argon as collision gas (Table 3) .
Resorufin formed during the CYP1A2 activity assay and 6β-hydroxytestosterone (CYP3A4) were quantified fluorometrically (Donato et al., 1993) and by HPLC analysis (Donato et al., 2006) , respectively. 
In vitro
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This article has not been copyedited and formatted. The final version may differ from this version. The CL int and CL max values were scaled to in vivo units using the scaling factors of 120 x 10 6 hepatocytes/g liver (Hakooz, et al., 2006) and 21.4 g liver/kg body weight (Davis and Morris, 1993).
Although no attempt was made to measure non-specific binding in the present study, previous reports indicate that the concentration of unbound drug in the incubation medium for alprazolam, midazolam and tolbutamide (Brown et al., 2007) would have been no more than marginally affected by such binding at the concentrations used; although no equivalent data for phenacetin was available, the log P of this compound indicates marginal binding also.
Comparison with human hepatocyte and in vivo clearances. The CL int and CL max values were compared with the equivalent values obtained using the commonly used suspended human cryopreserved hepatocyte system for phenacetin (Stringer et al., 2008) , tolbutamide (Brown et al., 2007) , alprazolam (Brown et al., 2007) and midazolam (Brown et al., 2007) after multiplication by the appropriate RAF (above).
The CL int and CL max values scaled to in vivo were compared with the equivalent human in vivo CL int values for phenacetin (Stringer et al., 2008) , tolbutamide (Brown et al., 2007) , alprazolam (Brown et al., 2007) and midazolam (Brown et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. formation by Ad-CYP1A2 cells followed simple Michaelis-Menten kinetics ( Fig. 2A) , whereas tolbutamide hydroxylation formation (Ad-CYP2C9) followed MichaelisMenten kinetics with a minor substrate inhibition (Fig. 2B) . Autoactivation kinetics or substrate inhibition kinetics was observed for 4-hydroxyalprazolam (Fig. 2C) approximately between 3-6-fold higher than the corresponding hepatocyte values (6.2-, 4.6-and 2.5-fold, respectively). In contrast, the RAF-scaled CL int for midazolam 1'-hydroxylation was 3.4-fold lower than that observed in suspended hepatocytes (77.9
µl/min/10 6 cells).
In vivo CL int was 615, 3.6, 3.7 and 314 ml/min/kg for phenacetin, tolbutamide, alprazolam and midazolam, respectively (Table 5 ). The equivalent scaled CL int (using RAF based on cultured hepatocytes) for the Ad-CYP system was 214, 1.74, 5.47 and 59.6 ml/min/kg (Table 5) , respectively, therefore, the in vitro/in vivo prediction of total in vivo CL int (based on the single CYP pathways) by this system was 0.3, 0.5, 1.50 and 0.2. For comparison, CL int previously reported for the commonly used suspended hepatocyte system was 34.7, 0.38, 2.1 and 200 ml/min/kg ( 
Discussion
Prediction of human clearance for P450 substrates has been extensively studied using human liver-derived in vitro systems. However, underestimation of human clearance using liver microsomes is common for many drugs . Compared to microsomes, the use of hepatocytes might seem to represent a significant improvement in the accuracy of clearance predictions because of utilisation of the intact cell including uptake phenomena and Phase II metabolic pathways. For this system, a reduced bias has been reported (Brown et al., 2007) . However, cryopreserved hepatocytes are not fully quantitative for predictions as a systematic underprediction of the in vivo value is obtained Brown et al., 2007; Riley et al., 2005) . Furthermore, wide individual variability, unresolved from bias and imprecision which are inherent in the use of human liver in vitro systems, combine to sustain considerable uncertainty in predicting clearance from in vitro (Hallifax and Houston, 2009 ).
Alternative strategies have been proposed for metabolism studies of P450 substrates, among them recombinant adenoviruses has proven as a versatile tool to transfer genes to a broad spectrum of cell types, including hepatic cells. By means of this strategy, high levels of functional transgene expression can be achieved without causing major changes in the expression of other constitutive or inducible hepatic genes (Castell et al., 1997) . The HepG2 cells transduced with adenoviral constructs have been used to study either the mechanisms involved in the control of the P450 expression or the role of a particular P450 enzyme in the bioactivation of hepatotoxicants (Bai and Cederbaum, 2004; Vignati et al., 2005; Zangar et al., 2008) . However, their utility in the prediction of metabolic clearance has not yet been explored.
In the present study, we examine the potential of using Ad-CYP transfected HepG2 cells for human clearance predictions. For this purpose, metabolite formation kinetics and the intrinsic clearance of phenacetin, tolbutamide, alprazolam and midazolam were analysed in Ad-CYP1A2, Ad-CYP2C9 or Ad-CYP3A4 HepG2 cells. The kinetic characteristics of metabolite formation for all four substrates conformed to previous observations in human liver in vitro systems. O-deethylation of phenacetin has been seen to follow two-site Michaelis-Menten kinetics in HLM (Tassaneeyakul et al., 1993; Venkatakrishnan et al., 1998) This article has not been copyedited and formatted. The final version may differ from this version. a Relative Activity Factor based on a ratio of marker activities (7-ethoxyresorufin O-deethylation, diclofenac 4'-hydroxylation or testosterone 6β-hydroxylation) in human cultured hepatocytes and Ad-CYP-transduced HepG2 cells. b Scaled using RAF for the primary cultured human hepatocytes.
c Data from Brown et al., 2007 (tolbutamide, alprazolam, midazolam) and Stringer et al., 2008 (phenacetin) . 
